A comparative study of the antidepressant effect of ondansetron and granisetron on Albino mice

Background: Ondansetron and granisetron are selective 5-HT receptor antagonists used as antiemetics. The present study as aimed at comparing the antidepressant activity of ondansetron and granisetron in animal experimental models.Methods: The study was done after obtaining approval from the institutional animal ethical committee of JJM Medical college, Davangere and CPCSEA. A total of 24 mice of either sex and of weight between 20-40g were included in the study. The antidepressant activity of ondansetron and granisetron was evaluated in mice using forced swim test model (FST) and tail suspension test model (TST). In both the experimental models animals were divided into 4 groups and received the following drugs- Group 1 (control) - normal saline 10mg/kg i.p, Group 2 (standard)-fluoxetine 10mg/kg i.p, Group 3(test drug 1), ondansetron 2mg/kg i.p, Group 4 (test drug 2)- granisetron 0.5mg/kg i.p. The duration of immobility was noted and compared amongst the 4 groups in both the models 60 min after drug administration. The observations were analysed using ANOVA (one way) and post hoc Tukey’s test.Results: The test drugs showed significant reduction in duration of immobility in both the models. In FST and TST models, granisetron (0.5mg/kg i.p) showed a significant reduction in immobility period of 10.33 sec and 67 secs respectively when compared to ondansetron (2mg/kg i.p) and the standard drug fluoxetine (10mg/kg i.p).Conclusions: The results of study suggest that granisetron may be useful as a potential candidate for treatment of depression. Hence further animal studies with different model for depression and clinical studies should be conducted in order to choose the better drug for treatment PONV which is often associated with depression

Gravity in the 3+1-Split Formalism II: Self-Duality and the Emergence of the Gravitational Chern-Simons in the Boundary

We study self-duality in the context of the 3+1-split formalism of gravity with non-zero cosmological constant. Lorentzian self-dual configurations are conformally flat spacetimes and have boundary data determined by classical solutions of the three-dimensional gravitational Chern-Simons. For Euclidean self-dual configurations, the relationship between their boundary initial positions and initial velocity is also determined by the three-dimensional gravitational Chern-Simons. Our results imply that bulk self-dual configurations are holographically described by the gravitational Chern-Simons theory which can either viewed as a boundary generating functional or as a boundary effective action.Comment: 25 pages; v2: minor improvements, references adde

Evaluation of efficacy of Carica papaya leaf extracts to increase platelet count in hydroxyurea induced thrombocytopenia in Albino rats

Background: Dengue is an infectious disease associated with high mortality and morbidity. Being a viral disease, there is no specific drug available for treatment. There are some reports that Carica papaya leaf extract may improve the clinical condition of dengue patients. However, to support this, at present, there is no systematically searched and synthesized evidence available. Hence this study was undertaken to compare the efficacy of commercial preparation of Carica papaya leaves with freshly prepared Carica papaya leaf extracted.Methods: 48 albino rats were randomly divided into eight groups of six each. Thrombocytopenia was induced by giving hydroxyurea (15mg/kg) orally. Group I and II served as saline and toxic control group respectively. Other six groups were given two different doses of either commercial extract or fresh extract orally for five days. 1ml of blood was withdrawn at baseline,3rd and 6th day of the study. Platelet, WBC, RBC count, clotting and bleeding time were determined.Results: Mean platelet count increased significantly on day 6 in both low dose (2.06 to 4.93lakh/mm3) and human equivalent dose (2.73 to 7.66lakh/mm3) of commercial extract groups compared to the toxic control group (p<0.05). Similarly, the mean platelet count increased significantly for human equivalent dose in fresh leaf extract group (3.17 to 4.69lakh/mm3) but the increase in low dose fresh extract (3.28 to 3.76lakh/mm3) was not significant. There was no significant rise in mean platelets count, mean RBC count, WBC count, decrease in mean bleeding and clotting time between commercial extract and fresh leaf extract group for both low dose and human equivalent dose.Conclusions: Efficacy of fresh leaf extract of Carica papaya was not inferior to commercial available preparation. Fresh Carica papaya leaf extract no doubt offers a potential therapeutic efficacy which is cost effective, more affordable and accessible treatment in patients with thrombocytopenia

Torsion and the Gravity Dual of Parity Symmetry Breaking in AdS4/CFT3 Holography

We study four dimensional gravity with a negative cosmological constant deformed by the Nieh-Yan torsional topological invariant with a spacetime-dependent coefficient. We find an exact solution of the Euclidean system, which we call the torsion vortex, having two asymptotic AdS4 regimes supported by a pseudoscalar with a kink profile. We propose that the torsion vortex is the holographic dual of a three dimensional system that exhibits distinct parity breaking vacua. The torsion vortex represents a (holographic) transition between these distinct vacua. We expect that from the boundary point of view, the torsion vortex represents a `domain wall' between the two distinct vacua. From a bulk point of view, we point out an intriguing identification of the parameters of the torsion vortex with those of an Abrikosov vortex in a Type I superconductor. Following the analogy, we find that external Kalb-Ramond flux then appears to support bubbles of flat spacetime within an asymptotically AdS geometry.Comment: 26 pages, 4 figures; v2: minor improvements, references adde

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

Patients with bone metastases from breast cancer often experience substantial skeletal complications – including debilitating bone pain – which negatively affect quality of life. Zoledronic acid (4 mg) has been demonstrated to reduce significantly the risk of skeletal complications in these patients and is administered via a short, 15-min infusion every 3 weeks, allowing the possibility for home administration. This study compared the efficacy and safety of zoledronic acid administered in the community setting vs the hospital setting in breast cancer patients with ⩾1 bone metastasis receiving hormonal therapy. After a lead-in phase of three infusions of 4 mg zoledronic acid in the hospital setting, 101 patients were randomized to receive three open-label infusions in the community or hospital setting, followed by three infusions in the opposite venue (a total of nine infusions). The Brief Pain Inventory (BPI) and the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) were used to assess potential benefits of zoledronic acid therapy. At study end, analysis of the BPI showed significant reductions in worst pain (P=0.008) and average pain in the last 7 days (P=0.039), and interference with general activity (P=0.012). In each case, there were significantly greater improvements in pain scores after treatment in the community setting compared with the hospital crossover setting for worst pain (P=0.021), average pain (P=0.003), and interference with general activity (P=0.001). Overall global health status showed a significant median improvement of 8.3% (P=0.013) at study end. Physical, emotional, and social functioning also showed significant overall improvement (P=0.013, 0.005, and 0.043, respectively). Furthermore, physical, role, and social functioning showed significantly greater improvements after treatment in the community setting compared with the hospital crossover setting (P=0.018, 0.001, and 0.026, respectively). There was no difference between hospital and community administration in renal or other toxicity, with zoledronic acid being well tolerated in both treatment settings. These data confirm the safety and quality-of-life benefits of zoledronic acid in breast cancer patients with bone metastases, particularly when administered in the community setting